Vitamin D Deficiency Prevention Policies in Iran: a Retrospective Policy Analysis
Overview
Affiliations
Aim: Iran has a higher prevalence of vitamin D deficiency (VDD) than the global level. This study aimed to assess VDD prevention policies in Iran through a policy analysis of agenda setting using the multiple streams framework (MSF).
Methods: Using Kingdon's MSF model, this qualitative analytical study performed a policy analysis on vitamin D-related policies in Iran. The policy documents were reviewed, and in-depth interviews were conducted with stakeholders ( = 27) using the framework analysis method. To categorize data and extract the related themes, MAXQDA version 10 was used.
Results: According to Kingdon's MSF theory, the problem stream included the high prevalence of VDD among Iranian infants (23.3%), adolescents (76%), and adults (59.1%). The policy stream was identified to focus on preventing programs for non-communicable diseases in the health sector. The political stream indicated that national and international support could provide a political climate for this issue.
Conclusion: According to our results, a window of opportunity for policymaking on VDD prevention has opened. However, there are some challenges related to the implementation of these policies. These include the dominance of a treatment-based view rather than a prevention-based approach in the health sector, economic problems, and restricted access to health services due to the outbreak of coronavirus disease 2019 (COVID-19). To strengthen and implement VDD prevention policies, the stakeholders need support from high-level policymakers.
Dehghani A, Rafraf M, Mohammadi-Nasrabadi F, Khodayari-Zarnaq R PLoS One. 2024; 19(10):e0311276.
PMID: 39361600 PMC: 11449356. DOI: 10.1371/journal.pone.0311276.
Ahangari R, Mohammadbeigi A, Miraj S, Rajabi N, Mohammadpour R J Prev Med Hyg. 2024; 65(1):E36-E42.
PMID: 38706771 PMC: 11066825. DOI: 10.15167/2421-4248/jpmh2024.65.1.3154.
Mohammadi A, Sadighi G, Nazeri Astaneh A, Tajabadi-Ebrahimi M, Dejam T Neuropsychopharmacol Rep. 2024; 44(2):389-398.
PMID: 38598329 PMC: 11144626. DOI: 10.1002/npr2.12431.
Mahmoodi M, Farajkhoda T, Nadjarzadeh A, Mahmoodabadi H Sci Rep. 2023; 13(1):16631.
PMID: 37789181 PMC: 10547791. DOI: 10.1038/s41598-023-43940-y.